Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
1 μg/mL |
10 μg/mL |
Assay dependent |
Not tested in other applications.
Calculated MW
Positive Control
3T3 (NIH) Cell Lysate(GTX27179) , Human Uterus Tissue Slide , Human Uterus Tissue Lysate
Form
Liquid
Buffer
PBS
Preservative
0.02% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
1 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
TIM-1 antibody was raised against a 16 amino acid synthetic peptide from near the amino terminus of human TIM-1.The immunogen is located within amino acids 50 - 100 of TIM-1.
Purification
Purified by antigen-affinity chromatography
Conjugation
Unconjugated
RRID
AB_10726144
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
hepatitis A virus cellular receptor 1 , CD365 , HAVCR , HAVCR-1 , KIM-1 , KIM1 , TIM , TIM-1 , TIM1 , TIMD-1 , TIMD1
Cellular Localization
Membrane
Background
The human form of TIM-1 was initially discovered as a membrane glycoprotein through which the hepatitis A virus can gain entry into a cell. It was also identified as kidney injury molecule 1 (Kim-1), a predicted adhesion molecule that is upregulated on the surfaces of kidney epithelia. It is also expressed on T helper 2 (Th2) cells of the immune system, and following the binding of its natural ligand TIM-4, stimulates T cell expansion and cytokine production in response to viral challenge. It has been suggested that hyperactivation of TIM-1 leads to an increased level of Th2 responsiveness and asthma susceptibility, and antibodies to TIM-1 may therefore be a novel approach to treating asthma.
Database
Research Area